AIM ImmunoTech and Erasmus MC Announce Progress on Phase 2 Trial for Ampligen and Imfinzi in Late-Stage Pancreatic Cancer

Quiver QuantitativeFeb 11 08:51 ET

AIM ImmunoTech Releases Virtual Investor "What This Means Segment"

GlobeNewswireFeb 11 08:45 ET

Express News | AIM ImmunoTech Announces That It Will Not Proceed With an Offering Pursuant to Its Registration Statement on Form S-1 Until After It Files Its Annual Report on Form 10-K for the Fiscal Year Ended December 31, 2024

ReutersFeb 11 08:30 ET

Petra Capital Keeps Their Buy Rating on Ai-Media Technologies Limited (AIM)

TipRanksFeb 9 20:08 ET · Ratings

Aim ImmunoTech Announces Its Initiation Of Plan To Advance Ampligen As A Vaccine Adjuvant For Avian Influenza

BenzingaFeb 7 08:53 ET

AIM ImmunoTech Announces a Planned Follow-up Clinical Study Evaluating a Combination Treatment of AIM's Ampligen and AstraZeneca's FluMist to Address the Recent Avian Influenza Outbreaks

GlobeNewswireFeb 7 08:50 ET